Glecaprevir/pibrentasvir (GLE/PIB) is a fixed-dose combination therapy approved for hepatitis C virus (HCV) that has expanded reach, reduced cost, and in certain patient populations, reduced HCV treatment duration, according to a recent review. The authors concluded:
- GLE/PIB is effective across all genotypes.
- GLE/PIB has been shown to be effective in HIV-infected patients, patients with chronic kidney disease (CKD), and Child-Pugh A-compensated cirrhosis.
- GLE/PIB is also effective for a shortened duration of 8 weeks in treatment-naïve non-cirrhotic patients.
Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. [Published online ahead of print May 29, 2018]. Hepatol Int. doi:10.1007/s12072-018-9873-y.
This Week's Must Reads
Relevance of Health Literacy to CV Health, Circulation; ePub 2018 Jun 4; Magnani, et al
Diabetes & Long-Term Kidney Disease, Diabetes Care; ePub 2018 Jun 1; Warren, et al
Maternal Loss of Control Over Eating, Am J Clin Nutr; ePub 2018 Jun 5; Micali, et al
Efficacy of Brief Behavioral Treatment for Insomnia, Sleep Medicine; ePub 2018 Jun 2; McCrae, et al
Opioid-Related Adverse Events in Surgical Patients, JAMA Surg; ePub 2018 May 23; Shafi, et al
Must Reads in Hepatitis
Glecaprevir/pibrentasvir Can Reduce HCV Tx Duration, Hepatol Int; ePub 2018 May 29; Abutaleb, et al
Estimates of HCV by Race and Sex in US, BMC Infect Dis; ePub 2018 May 16; Hall, et al
Efficacy of DAA Therapy for HCV in Older Adults, J Am Geriatr Soc; ePub 2018 May 25; Mazzarelli, et al
HCV Treatment in People Who Inject Drugs, Open Forum Infect Dis; ePub 2018 May 23; Alimohammadi, et al
Risk of HCV Among Vulnerable Populations, J Viral Hepat; ePub 2018 May 31; Aisyah, et al